Key facts
- It has raised $37.0M across 1 recorded rounds; the latest was Seed Round ($2.8M) in Dec 2019.
- Notable investors include Plug and Play Tech Center, United States Department of War, Ohio Department of Development, 1819 Innovation Hub, Berkeley Catalyst Fund Management — 6 tracked in total.
- Amplicore has filed 1 Form D with the SEC, most recently Jan 2020 ($2.8M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Amplicore
Funding rounds
1 roundsAbout Amplicore
Developer of injectable therapeutic drugs designed to treat degenerative musculoskeletal disorders to serve unmet medical needs. The company's drugs promote cartilage regeneration and suppress enzymatic activities to treat degenerative musculoskeletal disorders, enabling healthcare organizations to seamlessly provide relief to patients from joint pain.
- Sector
- Healthcare
- HQ
- Mason, OH, United States
- Founded
- 2018
- Employees
- 7
- Website
- amplicorepharma.com/
- Ownership
- Privately Held (backing)
Amplicore doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amplicore shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amplicore in its N-PORT filings yet. We sweep new filings monthly.